BEI Medical
This article was originally published in The Gray Sheet
Executive Summary
Sells its GyneSys and HysteroSys infertility catheter product lines to Johnson & Johnson's Ethicon division for $975,000 plus deferred payments based on future product sales. Under terms of the deal, BEI will supply the products to Ethicon on a non-exclusive basis for up to a year. The move reflects BEI's concentration on core products in women's health and a focus on developing its Hydro ThermAblator system, which is currently in clinical trials, for treatment of excessive uterine bleeding, the company says
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.